Recordati Licenses Exclusive Commercialization Rights of Juxtapid (lomitapide) from Aegerion Pharmaceuticals 

 Recordati Licenses Exclusive Commercialization Rights of Juxtapid (lomitapide) from Aegerion Pharmaceuticals 

Recordati Licenses Exclusive Commercialization Rights of Juxtapid (lomitapide) from Aegerion Pharmaceuticals 

Shots:

  • Aegerion (subsidiary of Novelion Therapeutics) to receive $25M upfront, $5M milestones, and royalties on sales of a product. Recordati to get exclusive commercialization rights for Aegerion’s Juxtapid in Japan
  • The focus of the agreement is to develop & commercialize Juxtapid and to strengthen Recordati’s portfolio of rare diseases products in Japan
  • Juxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor has received approval from Japan’s MHLW for homozygous familial hypercholesterolemia (HoFH), with sales of $10.8M in 2018, in Japan

Click here to read full press release/ article | Ref: Globe Newswire | Image: Amazon

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post